Abiopharma

News list

Marinus Pharmaceuticals Inc (MRNS)

Event
July 14, 2022, 11:11 UTC

(10% Negative) Marinus Pharmaceuticals, Inc. (MRNS) Announces Delay in voucher Trials for rare pediatric diseases Due to Pandemic-Related Challenges, Patient Enrollment Issues, Regulatory Process

Full text

News bot Oct. 2, 2025, 1:39 p.m.

📋 Marinus Pharmaceuticals, Inc. (MRNS) - Clinical Trial Update

Filing Date: 2022-07-14

Accepted: 2022-07-14 07:11:48

Event Type: Clinical Trial Update

Event Details:

Marinus Pharmaceuticals Inc (MRNS) Announces Clinical Trial Update Marinus Pharmaceuticals Inc (MRNS) provided an update on its clinical development programs. Clinical Development Highlights:

Drug Program: voucher, trials
Diseases/Conditions: rare pediatric diseases, $110 Million RADNOR
Clinical Stage: Phase 3, Phase 3 trial
Update Type: Trial Timeline Adjustment
Primary Factors: Pandemic-Related Challenges, Patient Enrollment, Regulatory Process, Regulatory Timeline
Collaboration: the Rare Pediatric Disease Priority Review Voucher
Updated Timeline: the fourth quarter of 2023

🔬 Clinical Development Pipeline (Marinus Pharmaceuticals, Inc.):

Product	Type	Development Stage	Therapeutic Area	Source
Ganaxolone	DRUG	Phase PHASE3	Tuberous Sclerosis Complex	ClinicalTrials.gov

💼 Business Developments:

Partnership
Acquisition: Not available
Licensing: Not available
Regulatory Approval
Executive Changes: Not available

Structured Data:

Company Name: Marinus Pharmaceuticals Inc
CIK: 0001267813
Ticker Symbol: MRNS
Period End Date: 2022-07-13
Document Type: 8-K